Abstract: Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a KD value of 1×10?8 M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.

Abstract: Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10?8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRP? without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.

Abstract: Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10?9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.

Abstract: Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.

Abstract: Provided is a separated antigen binding protein, containing at least one CDR in VH with the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 46; and at least one CDR in VL with the amino acid sequence as shown in SEQ ID NO: 2. Also provided are an immunoconjugate containing the separated antigen binding protein, nucleic acid coding the separated antigen binding protein, a carrier containing the separated antigen binding protein, a cell containing the nucleic acid or the carrier, a method for preparing the separated antigen binding protein, and use of the separated antigen binding protein.

Abstract: Provided is an antibody or an antigen-binding fragment thereof having one or more properties selected from the group consisting of: 1) capable of binding to a BCMA protein with a KD value of 1.8×10?9 M or lower; 2) capable of specifically recognizing a BCMA protein expressed on cell surfaces; 3) capable of being internalized by cells; and 4) capable of inhibiting tumors and/or tumor cell proliferation. The antibody can also be used to construct immunoconjugates. The antibody and immunoconjugates can all prevent or treat tumors.

Abstract: Provided are a fusion protein, and an immunoconjugate, a nucleic acid molecule, a carrier, a composition, a cell and a preparation method related thereto, for treating tumors and/or autoimmune diseases.

Abstract: Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRP? variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments.

Abstract: Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a KD value of 1×10?8M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.

Abstract: Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10?8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRP? without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.

Abstract: Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.

Abstract: This present invention provides a class of gene transfection reagents, which have a structure containing a nucleic acid binding domain and sugar targeting domain. The compounds are easy to synthesize and formulate. The formulated compound associates with DNA to form small particles with nearly neutral surface charge. The sugar domain plays a role as a tissue target ligand located on the surface of the nucleic acid complex, which promotes the receptor-mediated gene transfection. In the presence of proteins, these DNA complexes do not bind with proteins to form precipitates. The complexes are also stable when stored at 4° C. for a long time.